Leerink Partnrs Predicts Stronger Earnings for NeuroPace

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of NeuroPace in a report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of ($1.03) for the year, up from their previous estimate of ($1.10). The consensus estimate for NeuroPace’s current full-year earnings is ($1.08) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.03) EPS.

Other analysts also recently issued reports about the company. Wells Fargo & Company reduced their price objective on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a research note on Wednesday, August 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, NeuroPace currently has a consensus rating of “Moderate Buy” and an average target price of $14.60.

NeuroPace Price Performance

Shares of NASDAQ:NPCE opened at $8.98 on Friday. The company has a debt-to-equity ratio of 6.03, a quick ratio of 5.47 and a current ratio of 5.59. The business’s fifty day moving average price is $6.93 and its two-hundred day moving average price is $7.44. The stock has a market cap of $262.19 million, a PE ratio of -8.98 and a beta of 1.79. NeuroPace has a one year low of $5.45 and a one year high of $18.15.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. During the same period in the prior year, the business earned ($0.28) earnings per share.

Institutional Investors Weigh In On NeuroPace

Several hedge funds have recently modified their holdings of NPCE. Millennium Management LLC increased its position in NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of NeuroPace by 18.3% during the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after buying an additional 75,512 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of NeuroPace during the 1st quarter valued at $621,000. Bank of New York Mellon Corp acquired a new stake in shares of NeuroPace during the 2nd quarter worth $257,000. Finally, Geode Capital Management LLC raised its position in shares of NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after buying an additional 25,330 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 4,910 shares of NeuroPace stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $6.66, for a total value of $32,700.60. Following the completion of the sale, the insider now owns 5,540,104 shares in the company, valued at $36,897,092.64. The trade was a 0.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 257,590 shares of company stock worth $1,437,916. Insiders own 22.20% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.